DULAGLUTIDE (TRULICITY) prior authorization at Centene
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Centene reviews DULAGLUTIDE (TRULICITY) prior authorizations against its medical policy for GLP-1 Receptor Agonist [EPC]. The FDA-approved indication (2014) is INJECTABLE. Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Centene's medical policy URL referenced in the cover letter
Centene's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Marketplace network adequacy issues
- Medicaid step therapy
- Specialty drug exclusions
If the PA is denied
Centene gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus a peer-reviewed citation supporting DULAGLUTIDE (TRULICITY)for the patient's indication.
Medicare Advantage path: if Centene misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Contact Centene
- Provider portal: https://ambetterhealth.com/provider-resources
Frequently asked questions
What documentation does Centene need for DULAGLUTIDE (TRULICITY) prior auth?
Centene's typical PA packet for DULAGLUTIDE (TRULICITY): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For GLP-1 Receptor Agonist [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Centene?
Standard DULAGLUTIDE (TRULICITY) PA decisions at Centene: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Centene most often reject DULAGLUTIDE (TRULICITY) for?
Across Centene's book the common rejection patterns include: Marketplace network adequacy issues; Medicaid step therapy; Specialty drug exclusions. For DULAGLUTIDE (TRULICITY) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Centene on DULAGLUTIDE (TRULICITY)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the DULAGLUTIDE (TRULICITY) PA packet
Open ApprovalHelp — generate a DULAGLUTIDE (TRULICITY) prior-auth packet tailored to Centene's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com